Rhonda M Cooper-Dehoff

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. pmc Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study
    Rhonda M Cooper--DeHoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA
    J Am Heart Assoc 2:e000125. 2013
  2. pmc Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy
    Tobias Gerhard
    Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA
    BMC Med Res Methodol 12:119. 2012
  3. pmc Generic drugs for hypertension: are they really equivalent?
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL 32610 0486, USA
    Curr Hypertens Rep 15:340-5. 2013
  4. doi request reprint The next 10 years in antihypertensive treatment
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, PO Box 100486, Gainesville, FL 32610 0486, USA
    Expert Rev Cardiovasc Ther 11:669-71. 2013
  5. pmc Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort
    Jason H Karnes
    Division of Clinical Pharmacology, Vanderbilt University, Nashiville, TN 37232 0575, USA
    J Transl Med 11:12. 2013
  6. pmc Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response
    Stephen T Turner
    Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 10:47. 2012
  7. pmc Blood pressure lowering in patients with diabetes--one level might not fit all
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, PO Box 100486, University of Florida, Gainesville, FL 32610 0486, USA
    Nat Rev Cardiol 8:42-9. 2011
  8. pmc Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine, College of Pharmacy, University of Florida, 1600 SW Archer Rd, PO Box 100486, Gainesville, FL 32610 0486, USA
    JAMA 304:61-8. 2010
  9. pmc INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study
    Rhonda M Cooper-Dehoff
    University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, 1600 SW Archer Road, Box 100486, Gainesville, FL 32610 0486, USA
    Expert Rev Cardiovasc Ther 7:1329-40. 2009
  10. pmc Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1600 SW Archer Rd, Box 100486, Gainesville, FL 32610 0486, USA
    Hypertension 55:61-8. 2010

Collaborators

Detail Information

Publications55

  1. pmc Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study
    Rhonda M Cooper--DeHoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA
    J Am Heart Assoc 2:e000125. 2013
    ..Thiazide diuretics (TD), β blockers (BB), and renin-angiotensin system blockers (RASB) impact DM risk while calcium channel blockers (CCB) are neutral. DM risk associated with combinations is unclear...
  2. pmc Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy
    Tobias Gerhard
    Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA
    BMC Med Res Methodol 12:119. 2012
    ..Due to time-dependent confounding by blood pressure and differential loss to follow-up, it is difficult to estimate the effectiveness of aggressive versus conventional antihypertensive combination therapies in non-randomized comparisons...
  3. pmc Generic drugs for hypertension: are they really equivalent?
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL 32610 0486, USA
    Curr Hypertens Rep 15:340-5. 2013
    ....
  4. doi request reprint The next 10 years in antihypertensive treatment
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, PO Box 100486, Gainesville, FL 32610 0486, USA
    Expert Rev Cardiovasc Ther 11:669-71. 2013
    ..She is a member of the American Heart Association, American Society of Hypertension, American College of Cardiology and Florida Society of Hospital Pharmacists...
  5. pmc Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort
    Jason H Karnes
    Division of Clinical Pharmacology, Vanderbilt University, Nashiville, TN 37232 0575, USA
    J Transl Med 11:12. 2013
    ....
  6. pmc Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response
    Stephen T Turner
    Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 10:47. 2012
    ....
  7. pmc Blood pressure lowering in patients with diabetes--one level might not fit all
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, PO Box 100486, University of Florida, Gainesville, FL 32610 0486, USA
    Nat Rev Cardiol 8:42-9. 2011
    ..In the future, a personalized approach will maximize the benefits from treatment...
  8. pmc Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine, College of Pharmacy, University of Florida, 1600 SW Archer Rd, PO Box 100486, Gainesville, FL 32610 0486, USA
    JAMA 304:61-8. 2010
    ..Hypertension guidelines advocate treating systolic blood pressure (BP) to less than 130 mm Hg for patients with diabetes mellitus; however, data are lacking for the growing population who also have coronary artery disease (CAD)...
  9. pmc INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study
    Rhonda M Cooper-Dehoff
    University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, 1600 SW Archer Road, Box 100486, Gainesville, FL 32610 0486, USA
    Expert Rev Cardiovasc Ther 7:1329-40. 2009
    ..g., risk for diabetes) and not necessarily that any one drug be given to all...
  10. pmc Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1600 SW Archer Rd, Box 100486, Gainesville, FL 32610 0486, USA
    Hypertension 55:61-8. 2010
    ..19 [95% CI: 1.35 to 7.52]). Development of adverse metabolic effect, including new-onset diabetes mellitus associated with short-term exposure to hydrochlorothiazide and atenolol was more common in those with abdominal obesity...
  11. pmc G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension
    Alexander G Vandell
    Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida College of Pharmacy, 1600 SW Archer Rd, Room PG 22, Box 100486, Gainesville, FL 32610 0486, USA
    Hypertension 60:957-64. 2012
    ..The associations with GRK4 variant alleles were stronger in patients who were also ADRB1 389R homozygotes, suggesting a potential interaction between these 2 genes...
  12. pmc Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes
    Caitrin W McDonough
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA
    Hypertension 62:48-54. 2013
    ..These specific genetic associations and our risk score provide insight into a potential approach to personalized antihypertensive treatment selection...
  13. pmc Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study
    Yan Gong
    Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, 32610, USA
    Circ Cardiovasc Genet 5:686-91. 2012
    ..Our hypothesis is that the loci/SNPs associated with BP/hypertension are also associated with BP response to antihypertensive drugs...
  14. pmc Systolic blood pressure and subjective well-being in patients with coronary artery disease
    Yan Gong
    College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    Clin Cardiol 32:627-32. 2009
    ..Limited information exists regarding the association between subjective well-being (SWB) and systolic blood pressure (SBP) among hypertensive patients with coronary artery disease (CAD)...
  15. pmc CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
    Amber L Beitelshees
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, FL, USA
    Circ Cardiovasc Genet 2:362-70. 2009
    ..The gene encoding the target of calcium channel blockers, the alpha1c-subunit of the L-type calcium channel (CACNA1C), has not been well characterized, and only small pharmacogenetic studies testing this gene have been published to date...
  16. ncbi request reprint Predictors of adverse outcome among patients with hypertension and coronary artery disease
    Carl J Pepine
    Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida 32610 0277, USA
    J Am Coll Cardiol 47:547-51. 2006
    ..We sought to determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD)...
  17. ncbi request reprint Characteristics of contemporary patients with hypertension and coronary artery disease
    Rhonda M Cooper-Dehoff
    Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 0277, USA
    Clin Cardiol 27:571-6. 2004
    ..This is particularly true for black and Hispanic patients who have been underrepresented in randomized CAD trials...
  18. pmc Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide
    Julio D Duarte
    Center for Pharmacogenomics and Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL 32610, USA
    J Transl Med 10:56. 2012
    ..This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure...
  19. ncbi request reprint Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST)
    Rhonda M Cooper-Dehoff
    University of Florida College of Medicine, Gainesville, FL, USA
    Am Heart J 151:1072-9. 2006
    ..People of Hispanic origin are the fastest growing ethnic minority in the United States and often have hypertension and other comorbidities which increase the risk associated with coronary artery disease (CAD)...
  20. pmc Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST)
    David E Winchester
    Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida
    Clin Cardiol 36:442-7. 2013
    ..We conducted this prespecified analysis of the International Verapamil/Trandolapril Study (INVEST) to assess relationships between angina, blood pressure (BP), and mortality among elderly, hypertensive CAD patients...
  21. pmc Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes
    Jason H Karnes
    aDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee bDepartment of Pharmacotherapy and Translational Research cDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics dDepartment of Medicine, Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida eOffice of Clinical Pharmacology, Food and Drug Administration, Silver Spring, Maryland, USA
    Pharmacogenet Genomics 23:697-705. 2013
    ..We investigated the association of tag SNPs in TCF7L2 with thiazide-induced NOD...
  22. pmc Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study)
    Martin Brunner
    Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, USA
    Am J Cardiol 99:1549-54. 2007
    ..Race was associated with diastolic BP response, although the difference is likely not to be clinically significant and AGTR1 genotype was not associated with BP response...
  23. pmc KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)
    Amber L Beitelshees
    Department of Pharmacy Practice, University of Florida, College of Pharmacy, Gainesville, USA
    Pharmacogenet Genomics 17:719-29. 2007
    ....
  24. pmc Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST])
    Scott J Denardo
    University of Florida College of Medicine, Gainesville, FL, USA
    Am J Cardiol 106:498-503. 2010
    ..The management of BP might, therefore, require modification of targets according to the revascularization strategy to improve outcomes...
  25. pmc Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease
    Yan Gong
    Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Circ Cardiovasc Genet 4:169-78. 2011
    ..We investigated the hypothesis that 9p21 polymorphisms are associated with increased risk for adverse cardiovascular outcomes in patients with documented CAD...
  26. pmc Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients
    Maximilian T Lobmeyer
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida 32610, USA
    Pharmacogenet Genomics 21:42-9. 2011
    ....
  27. doi request reprint Harmful effects of NSAIDs among patients with hypertension and coronary artery disease
    Anthony A Bavry
    Department of Medicine, College of Medicine, University of Florida, Gainesville, 32610 0277, USA
    Am J Med 124:614-20. 2011
    ..There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensive patients with coronary artery disease...
  28. pmc Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study
    Julie A Johnson
    University of Florida College of Pharmacy and Center for Pharmacogenomics, Gainesville, USA
    Am Heart J 157:442-9. 2009
    ..Selection of antihypertensive therapy is often empiric, and use of genetic information to guide drug therapy selection holds future promise...
  29. pmc Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy
    Scott J Denardo
    Division of Cardiovascular Medicine, University of Florida College of Medicine, 1600 SW Archer Rd, PO Box 100277, Gainesville, FL 32610, USA
    Hypertension 53:624-30. 2009
    ..Because, as a group, revascularized patients with hypertension had worse outcomes compared with nonrevascularized patients, management of blood pressure to a specific target in future studies could result in improved outcomes...
  30. pmc Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES)
    Tobias Gerhard
    College of Pharmacy, University of Florida, Gainesville, FL 32610 0486, USA
    Am Heart J 156:397-404. 2008
    ..The alpha-adducin (ADD1) Gly460Trp polymorphism has been associated with hypertension and response to diuretic therapy, but controversy exists...
  31. pmc Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study
    ELVIN TYRONE PRICE
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida College of Medicine, Gainesville, FL, USA
    Pharmacogenet Genomics 21:333-40. 2011
    ....
  32. pmc Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy
    Scott J Denardo
    Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Am J Med 123:719-26. 2010
    ..Our understanding of the growing population of very old patients (aged >or=80 years) with coronary artery disease and hypertension is limited, particularly the relationship between blood pressure and adverse outcomes...
  33. pmc Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)
    Yuxin Niu
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
    Circ Cardiovasc Genet 3:548-55. 2010
    ..Single-nucleotide polymorphisms (SNPs) within the regulatory β2 subunit of the voltage-gated calcium channel (CACNB2) may contribute to variable treatment response to antihypertensive drugs and adverse cardiovascular outcomes...
  34. ncbi request reprint Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST
    Rhonda M Cooper-Dehoff
    Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    J Womens Health (Larchmt) 16:632-40. 2007
    ..Prospective data regarding blood pressure (BP) control and cardiovascular (CV) outcomes in Hispanic women are lacking...
  35. pmc Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics
    Caitrin W McDonough
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, Florida 32610 0486, USA
    J Hypertens 31:698-704. 2013
    ..We sought to further evaluate associations between NEDD4L polymorphisms, blood pressure response and cardiovascular outcomes with thiazide diuretics and β-blockers...
  36. pmc Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
    Steven M Smith
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Pharmacotherapy 29:1157-65. 2009
    ..To determine whether changes in serum glucose, serum potassium, and plasma insulin levels are correlated in a cohort of hypertensive patients...
  37. pmc Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy
    Anthony A Bavry
    Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Rd, PO Box 100277, Gainesville, FL 32610 0277, USA
    Hypertension 55:48-53. 2010
    ..PAD patients displayed a J-shape relationship with systolic blood pressure and the primary outcome, although individuals without PAD did not. PAD patients may require a different target blood pressure than those without PAD...
  38. ncbi request reprint Cardiovascular therapies and risk for development of diabetes
    Carl J Pepine
    Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida 32610 0277, USA
    J Am Coll Cardiol 44:509-12. 2004
    ..Physicians should consider this possible diabetes consequence when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of developing diabetes...
  39. pmc Simple integer risk score to determine prognosis of patients with hypertension and chronic stable coronary artery disease
    Anthony A Bavry
    College of Medicine, University of Florida, Gainesville, FL
    J Am Heart Assoc 2:e000205. 2013
    ..It is difficult to accurately determine prognosis of patients with hypertension and chronic stable coronary artery disease (CAD). Our aim was to construct a risk score for predicting important adverse events in this population...
  40. pmc PROX1 Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment
    Yan Gong
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida
    Pharmacotherapy 34:123-30. 2014
    ....
  41. ncbi request reprint Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST)
    Issam Zineh
    Department of Pharmacy Practice, College of Pharmacy University of Florida, Gainesville, Florida 32610, USA
    Clin Cardiol 28:321-8. 2005
    ....
  42. pmc Atenolol exposure and risk for development of adverse metabolic effects: a pilot study
    Hrishikesh A Navare
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, College of Medicine, University of Florida, Gainesville, Florida 32610 0486, USA
    Pharmacotherapy 30:872-8. 2010
    ..To evaluate whether the level of systemic exposure to atenolol explains observed interindividual differences in adverse metabolic responses...
  43. ncbi request reprint Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension
    Steven M Smith
    aDepartment of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado bDepartment of Pharmacotherapy and Translational Research, College of Pharmacy cDivision of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida dDivision of Cardiology, St Luke s Roosevelt Hospital, New York eDepartment of Preventive Medicine, Rush University, Chicago, Illinois fDepartments of Medicine and Epidemiology, Schools of Medicine and Public Health, University of Alabama Birmingham, Birmingham, Alabama, USA
    J Hypertens 32:635-43. 2014
    ..In this post-hoc INternational VErapamil SR-Trandolapril STudy (INVEST) analysis, we assessed prevalence, predictors, and impact on outcomes of res-HTN in CAD patients with hypertension...
  44. pmc Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension
    Michael A Pacanowski
    Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, Florida, USA
    Am J Hypertens 22:748-53. 2009
    ..We examined genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure (BP) control, and cardiovascular events in elderly, hypertensive coronary artery disease (CAD) patients...
  45. pmc Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum
    Rhonda M Cooper-Dehoff
    Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida 32610 0277, USA
    J Am Coll Cardiol 53:S28-34. 2009
    ..These considerations have particular importance in younger patients who may also have pre-diabetes or the metabolic syndrome and who are likely to require therapy over the course of decades...
  46. pmc Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation
    Michael A Pacanowski
    Department of Pharmacy Practice and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, FL, USA
    J Transl Med 6:11. 2008
    ..Adrenergic gene polymorphisms are associated with cardiovascular and metabolic phenotypes. We investigated the influence of adrenergic gene polymorphisms on cardiovascular risk in women with suspected myocardial ischemia...
  47. pmc Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation
    Anthony A Bavry
    North Florida South Georgia Veterans Health System, Gainesville, FL Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL Electronic address
    Am Heart J 167:826-32. 2014
    ..Angiotensin II inhibition may improve endothelial function, but with continued treatment, "aldosterone escape" may occur. Thus, it is unknown if adding aldosterone blockade further improves endothelial function...
  48. pmc In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Hea
    Daniel F Pauly
    Division of Cardiovascular Medicine, University of Florida, Gainesville, USA
    Am Heart J 162:678-84. 2011
    ..Although microvascular dysfunction has been suggested to explain this syndrome and recently was found to predict adverse outcomes, the mechanisms and treatments remain unclear...
  49. pmc Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics
    Julio D Duarte
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610 0486, USA
    Expert Rev Cardiovasc Ther 8:793-802. 2010
    ....
  50. pmc Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study
    Steven M Smith
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL
    J Am Heart Assoc 3:e000660. 2014
    ....
  51. pmc Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects
    Jason H Karnes
    Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, PO Box 100486, Gainesville, FL 32610 0486, USA
    Expert Rev Cardiovasc Ther 7:689-702. 2009
    ..This review summarizes the data related to the benefits of blood pressure reduction as well as the adverse metabolic effects and new-onset diabetes associated with some medications...
  52. pmc Metabolic syndrome and cardiovascular disease: challenges and opportunities
    Rhonda M Cooper-Dehoff
    Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 0277, USA
    Clin Cardiol 30:593-7. 2007
    ....
  53. doi request reprint Calcium antagonists in the treatment of coronary artery disease
    Rhonda M Cooper-Dehoff
    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, PO Box 100486, 1600 SW Archer Road, Gainesville, FL 32610 0486, USA
    Curr Opin Pharmacol 13:301-8. 2013
    ..Therefore, CAs may be ideal for managing CAD and may be considered as a first-line treatment option, depending on individual patient characteristics. ..
  54. ncbi request reprint Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris
    Carl J Pepine
    University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Am J Cardiol 91:274-9. 2003
    ..Thus, nisoldipine-ER and amlodipine provided comparable antihypertensive and anti-ischemic efficacy, and both were generally well tolerated...
  55. pmc Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
    Caitrin W McDonough
    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, Florida, United States of America
    PLoS ONE 8:e76984. 2013
    ..0279). In conclusion, we identified multiple gene regions associated with atenolol induced HDL-C change that were consistent across race groups, several with functional implications or prior associations with HDL-C. ..